Molecular Diversity at the CYP2D6 Locus in Healthy and Schizophrenic Southern Brazilians

• Nebert DW , RussellDW: Clinical importance of the cytochromes P450.Lancet360 , 1155–1162 (2002).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M , Rodriguez-AntonaC: Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.Philos. Trans. R. Soc. Lond. B Biol. Sci.360 , 1563–1570 (2005).
   PubMed Web of Science ®Google Scholar
• Phillips KA , VeenstraDL, OrenE, LeeJK, SadeeW: Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review.JAMA286 , 2270–2279 (2001).
   PubMed Web of Science ®Google Scholar
• Tiwari AK , DeshpandeSN, RaoAR et al.: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.Schizophr. Res.75 , 21–26 (2005).
   PubMed Web of Science ®Google Scholar
• Bradford LD : CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics3 , 229–243 (2002).
   PubMed Web of Science ®Google Scholar
• Kimura S , UmenoM, SkodaRC, MeyerUA, GonzalezFJ: The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.Am. J. Hum. Genet.45 , 889–904 (1989).
   PubMed Web of Science ®Google Scholar
• de Leon J : AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.Expert Rev. Mol. Diagn.6 , 277–286 (2006).
   PubMed Web of Science ®Google Scholar
• Llerena A , DoradoP, Peñas-LledóEM: Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.Pharmacogenomics10 , 17–28 (2009).
   PubMed Web of Science ®Google Scholar
• Jönsson EG , DahlML, RohHK, JerlingM, SedvallGC: Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.Psychiatr. Genet.8 , 25–28 (1998).
   PubMed Web of Science ®Google Scholar
• Siegle I , FritzP, EckhardtK, ZangerUM, EichelbaumM: Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain.Pharmacogenetics11 , 237–245 (2001).
   PubMedGoogle Scholar
• Funae Y , KishimotoW, ChoT, NiwaT, HiroiT: CYP2D in the brain.Drug Metab. Pharmacokinet.18 , 337–349 (2003).
   PubMedGoogle Scholar
• Brockmöller J , KirchheinerJ, SchmiderJ et al.: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.Clin. Pharmacol. Ther.72 , 438–452 (2002).
   PubMed Web of Science ®Google Scholar
• Llerena A , DoradoP, Peñas-LledóEM, CáceresMC, De la Rubia A: Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J.7 , 408–410 (2007).
   PubMed Web of Science ®Google Scholar
• Dahl AV , LowertA, AssersonS, BiarkingL et al.: Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark.Hum. Psychopharmacol. Clin. Exp.13 , 509–511 (1998).
   Web of Science ®Google Scholar
• Dawson E , PowellJF, NöthenMM et al.: An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.Psychiatr. Genet.4 , 215–218 (1994).
   PubMedGoogle Scholar
• Daniels J , WilliamsJ, AshersonP, McGuffinP, OwenM: No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT).Am. J. Med. Genet.60 , 85–87 (1995).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M , WildMJ, KitteringhamNR et al.: Lack association between schizophrenia and the CYP2D6 gene polymorphisms.Am. J. Med. Genet.67 , 236–237 (1996).
   PubMed Web of Science ®Google Scholar
• Chen CH , HungCC, WeiFC, KoongFJ: Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan.Psychiatr. Genet.11 , 153–155 (2001).
   PubMed Web of Science ®Google Scholar
• Fernández-Santander A , SantiagoC, Díez-DuránS et al.: Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?Hum. Psychopharmacol.23 , 533–536 (2008).
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB , GamaCS, LobatoMI et al.: Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics.Pharmacogenet. Genomics18 , 599–609 (2008).
   PubMed Web of Science ®Google Scholar
• Salzano FM , Freire-MaiaN: Problems in Human Biology. A study of Brazilian Populations. Wayne State University Press, MI, USA (1970).
   Google Scholar
• Heidrich EM , HutzMH, SalzanoFM, CoimbraCEA, SantosRV: D1S80 locus variability in three Brazilian ethnic groups.Hum Biol.67 , 311–319 (1995).
   PubMed Web of Science ®Google Scholar
• Bortolini MC , SalzanoFM, ZagoMA, Silva Jr WA, Weimer TA: Genetic variability in two Brazilian ethnic groups: a comparison of mitochondrial and protein data. Am. J. Phys. Anthropol.103 , 147–156 (1998).
   Web of Science ®Google Scholar
• Dornelles CL , Callegari-JacquesSM, RobinsonWM et al.: Genetic, surnames, grandparents nationalities, and ethnic admixture in southern Brazil – do the patterns of variation coincide?Genet. Mol. Biol.22 , 151–161 (1999).
   Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, text revision: DSM-IV-TR(4th Edition). American Psychiatric Press, Washington DC, USA (1994).
   Google Scholar
• Lahiri DK , NurnbergerJI: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies.Nucleic Acids Res.19 , 5444 (1991).
   PubMed Web of Science ®Google Scholar
• Abramson JH , GahlingerPM: Computer Programs for Epidemiologists: PEPI. (Version 4.0). Sagesbrush Press, UT, USA (2001).
   Google Scholar
• Salzano FM , BortoliniMC: The Evolution and Genetics of Latin American Populations. Cambridge University Press, Cambridge, UK (2002).
   Google Scholar
• Callegari-Jacques SM , GrattapagliaD, SalzanoFM et al.: Historical genetics-spatiotemporal analysis on the formation of the Brazilian population.Am. J. Hum. Biol.15 , 824–834 (2003).
   PubMed Web of Science ®Google Scholar
• Zembrzuski VM , Callegari-JacquesSM, HutzMH: Application of an African ancestry index as a genomic control approach in a Brazilian population.Ann. Hum. Genet.70 , 822–828 (2006).
   PubMed Web of Science ®Google Scholar
• de Leon J , SusceMT, JohnsonM et al.: DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.CNS Spectr.14 , 19–34 (2009).
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM , HaslerJA: Genetic polymorphism of drug metabolizing enzymes in African populations: implications for the use of neuroleptics and antidepressants.Brain Res. Bull.44 , 561–571 (1997).
   PubMed Web of Science ®Google Scholar
• Cai WM , NikoloffDM, PanRM et al.: CYP2D6 genetic variation in healthy adults and psychiatric African–American subjects: implications for clinical practice and genetic testing.Pharmacogenomics J.6 , 343–350 (2006).
   PubMed Web of Science ®Google Scholar
• Sistonen J , SajantilaA, LaoO, CoranderJ, BarbujaniG, FuselliS: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.Pharmacogenet. Genomics17 , 93–101 (2007).
   PubMed Web of Science ®Google Scholar
• Lovlie R , DalyAK, MolvenA, IdleJR, SteenVM: Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.FEBS Lett.392 , 30–34 (1996).
   PubMed Web of Science ®Google Scholar
• Agundez JA , LedesmaMC, LaderoJM, BenitezJ: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.Clin. Pharmacol. Ther.57 , 265–269 (1995).
   PubMed Web of Science ®Google Scholar
• Bernal ML , SinuesB, JohanssonI et al.: Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.Pharmacogenetics9 , 657–660 (1999).
   PubMedGoogle Scholar
• Ingelman-Sundberg M : Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.Pharmacogenomics J.5 , 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Johansson I , LundqvistE, BertilssonL, DahlML, SjöqvistF, Ingelman-SundbergM: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.Proc. Natl Acad. Sci. USA90 , 11825–11829 (1993).
   PubMed Web of Science ®Google Scholar
• de Leon J , ArranzMJ, RuañoG: Pharmacogenetic testing in psychiatry: a review of features and clinical realities.Clin. Lab. Med.28 , 599–617 (2008).
   PubMed Web of Science ®Google Scholar
• Daly AK : Pharmacogenetics of the cytochromes P450.Curr. Top. Med. Chem.4 , 1733–1744 (2004).
   PubMed Web of Science ®Google Scholar
• Dorado P , Peñas-LledóEM, LlerenaA: CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.Pharmacogenomics8 , 1597–1608 (2007).
   PubMed Web of Science ®Google Scholar
• de Leon J : The future (or lack of future) of personalized prescription in psychiatry.Pharmacol. Res.59 , 81–89 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch T , PriceA: The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.Am. Fam. Physician.76 , 391–396 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou SF , DiYM, ChanE et al.: Clinical pharmacogenetics and potential application in personalized medicine.Curr. Drug Metab.9 , 738–784 (2008).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , PenaSD: Pharmacogenomics in the Americas: the impact of genetic admixture.Curr. Drug Targets7 , 1649–1658 (2006).
   PubMed Web of Science ®Google Scholar

▪ Website

• Human cytochrome P450 (CYP) allele nomenclature committee recommendation. www.cypalleles.ki.se/cyp2d6.htm
   Google Scholar